Metastatic Colo-Rectal Cancer, 2005-2008: Treatment results
Introduction: Colo-rectal cancer has 10% prevalence, among all of the cancer proportionally and also it is the third common cancer in the both sexes. Two recently introduced active drugs in the treatment of advanced colorectal cancer (ACC) are irinotecan and oxaliplatin. The combinations of oxalipla...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2009-12-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/228 |
| _version_ | 1797719908831723520 |
|---|---|
| author | Mozaffar Aznab A Tabarroki Gh Mohsseni F Farshian K Kavyani |
| author_facet | Mozaffar Aznab A Tabarroki Gh Mohsseni F Farshian K Kavyani |
| author_sort | Mozaffar Aznab |
| collection | DOAJ |
| description | Introduction: Colo-rectal cancer has 10% prevalence, among all of the cancer proportionally and also it is the third common cancer in the both sexes. Two recently introduced active drugs in the treatment of advanced colorectal cancer (ACC) are irinotecan and oxaliplatin. The combinations of oxaliplatin (OXA) or irinotecan (IRI) with 5FU-LV have been accepted as standard treatment for metastatic colorectal cancer.
Patients and Methods: fifty four patients with colo-rectal cancer who came to the Oncology Clinic of Kermanshah University were assessed over a period of 4 years (2005-2008). All cases in stage III were treated by FOLFOX, unlike the patients in Stage IV treated with FOLFOX during 8 cycles fallowed by FOLFIRI in the same cycles (Sequential method).
Results: the age average was less (49.1 years versus 55 years) than in other studies (6). A parallel analyzation of solid data, overall survival (OS), progression free survival (PFS) were 18 and 17.3 months, respectively.
Conclusion: FOLFOX and FOLFIRI were administrated in 8 cycles each concomitantly (Sequential form) which provided considerable response with manageable complications. The result of the treatment in the study was correlated with other trials utilizing more modern procedures of medication like ‘Target therapies’ (OS; 18.4m for CT versus 19-20m for target therapies). |
| first_indexed | 2024-03-12T09:12:36Z |
| format | Article |
| id | doaj.art-2fdc77c73b80419a8eea4ee379f5fc13 |
| institution | Directory Open Access Journal |
| issn | 2008-2207 |
| language | English |
| last_indexed | 2024-03-12T09:12:36Z |
| publishDate | 2009-12-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | International Journal of Hematology-Oncology and Stem Cell Research |
| spelling | doaj.art-2fdc77c73b80419a8eea4ee379f5fc132023-09-02T14:54:59ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072009-12-0134Metastatic Colo-Rectal Cancer, 2005-2008: Treatment resultsMozaffar Aznab0A Tabarroki1Gh Mohsseni2F Farshian3K Kavyani4Hematology-Oncology Department, Kermanshah University of Medical Science (KUMS)Hematology-Oncology Department, Kermanshah University of Medical Science (KUMS)Hematology-Oncology Department, Kermanshah University of Medical Science (KUMS)Faculty of Medical Sciences, Kermanshah University of Medical Science (KUMS)Statistic Department, Kermanshah University of Medical Science (KUMS)Introduction: Colo-rectal cancer has 10% prevalence, among all of the cancer proportionally and also it is the third common cancer in the both sexes. Two recently introduced active drugs in the treatment of advanced colorectal cancer (ACC) are irinotecan and oxaliplatin. The combinations of oxaliplatin (OXA) or irinotecan (IRI) with 5FU-LV have been accepted as standard treatment for metastatic colorectal cancer. Patients and Methods: fifty four patients with colo-rectal cancer who came to the Oncology Clinic of Kermanshah University were assessed over a period of 4 years (2005-2008). All cases in stage III were treated by FOLFOX, unlike the patients in Stage IV treated with FOLFOX during 8 cycles fallowed by FOLFIRI in the same cycles (Sequential method). Results: the age average was less (49.1 years versus 55 years) than in other studies (6). A parallel analyzation of solid data, overall survival (OS), progression free survival (PFS) were 18 and 17.3 months, respectively. Conclusion: FOLFOX and FOLFIRI were administrated in 8 cycles each concomitantly (Sequential form) which provided considerable response with manageable complications. The result of the treatment in the study was correlated with other trials utilizing more modern procedures of medication like ‘Target therapies’ (OS; 18.4m for CT versus 19-20m for target therapies).https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/228OxalliplatinIrrinotecanColorectal cancer |
| spellingShingle | Mozaffar Aznab A Tabarroki Gh Mohsseni F Farshian K Kavyani Metastatic Colo-Rectal Cancer, 2005-2008: Treatment results International Journal of Hematology-Oncology and Stem Cell Research Oxalliplatin Irrinotecan Colorectal cancer |
| title | Metastatic Colo-Rectal Cancer, 2005-2008: Treatment results |
| title_full | Metastatic Colo-Rectal Cancer, 2005-2008: Treatment results |
| title_fullStr | Metastatic Colo-Rectal Cancer, 2005-2008: Treatment results |
| title_full_unstemmed | Metastatic Colo-Rectal Cancer, 2005-2008: Treatment results |
| title_short | Metastatic Colo-Rectal Cancer, 2005-2008: Treatment results |
| title_sort | metastatic colo rectal cancer 2005 2008 treatment results |
| topic | Oxalliplatin Irrinotecan Colorectal cancer |
| url | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/228 |
| work_keys_str_mv | AT mozaffaraznab metastaticcolorectalcancer20052008treatmentresults AT atabarroki metastaticcolorectalcancer20052008treatmentresults AT ghmohsseni metastaticcolorectalcancer20052008treatmentresults AT ffarshian metastaticcolorectalcancer20052008treatmentresults AT kkavyani metastaticcolorectalcancer20052008treatmentresults |